Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1062858/full |
| _version_ | 1811213781017034752 |
|---|---|
| author | María Torrente María Torrente Mariola Blanco Fabio Franco Yago Garitaonaindia Virginia Calvo Ana Collazo-Lorduy Lourdes Gutiérrez Juan Cristóbal Sánchez Aranzazu González-del-Alba Roberto Hernández Miriam Méndez Blanca Cantos Beatriz Núñez Pedro A. C. Sousa Mariano Provencio |
| author_facet | María Torrente María Torrente Mariola Blanco Fabio Franco Yago Garitaonaindia Virginia Calvo Ana Collazo-Lorduy Lourdes Gutiérrez Juan Cristóbal Sánchez Aranzazu González-del-Alba Roberto Hernández Miriam Méndez Blanca Cantos Beatriz Núñez Pedro A. C. Sousa Mariano Provencio |
| author_sort | María Torrente |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true incidence is underestimated in clinical trials. The aim of this study is to assess the incidence and identify risk factors for developing a cardiac event in patients treated with ICIs.MethodsWe conducted a single-institution retrospective study, including patients treated with ICIs in our center. The main outcomes were cardiac events (CE) and cardiovascular death.ResultsA total of 378 patients were analyzed. The incidence of CE was 16.7%, during a median follow-up of 50.5 months. The multivariable analysis showed that age, a history of arrhythmia or ischemic heart disease, and prior immune-related adverse events were significantly associated with CE.ConclusionCE during ICI treatment are more common than currently appreciated. A complete initial cardiovascular evaluation is recommended, especially in high-risk patients, being necessary a multidisciplinary approach of a specialized cardio-oncology team. |
| first_indexed | 2024-04-12T05:51:57Z |
| format | Article |
| id | doaj.art-79d816dc257c4b7d8758d885556f05a2 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T05:51:57Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-79d816dc257c4b7d8758d885556f05a22022-12-22T03:45:17ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-12-01910.3389/fcvm.2022.10628581062858Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitorsMaría Torrente0María Torrente1Mariola Blanco2Fabio Franco3Yago Garitaonaindia4Virginia Calvo5Ana Collazo-Lorduy6Lourdes Gutiérrez7Juan Cristóbal Sánchez8Aranzazu González-del-Alba9Roberto Hernández10Miriam Méndez11Blanca Cantos12Beatriz Núñez13Pedro A. C. Sousa14Mariano Provencio15Department of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainFaculty of Health Sciences, Francisco de Vitoria University, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainDepartment of Electrical Engineering, NOVA School of Science and Technology, Universidade Nova de Lisboa, Lisbon, PortugalDepartment of Medical Oncology, Puerta de Hierro Majadahonda University Hospital, Madrid, SpainBackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true incidence is underestimated in clinical trials. The aim of this study is to assess the incidence and identify risk factors for developing a cardiac event in patients treated with ICIs.MethodsWe conducted a single-institution retrospective study, including patients treated with ICIs in our center. The main outcomes were cardiac events (CE) and cardiovascular death.ResultsA total of 378 patients were analyzed. The incidence of CE was 16.7%, during a median follow-up of 50.5 months. The multivariable analysis showed that age, a history of arrhythmia or ischemic heart disease, and prior immune-related adverse events were significantly associated with CE.ConclusionCE during ICI treatment are more common than currently appreciated. A complete initial cardiovascular evaluation is recommended, especially in high-risk patients, being necessary a multidisciplinary approach of a specialized cardio-oncology team.https://www.frontiersin.org/articles/10.3389/fcvm.2022.1062858/fullcardiovascular eventimmune checkpoint inhibitorsmyocarditiscardiotoxicityrisk factors |
| spellingShingle | María Torrente María Torrente Mariola Blanco Fabio Franco Yago Garitaonaindia Virginia Calvo Ana Collazo-Lorduy Lourdes Gutiérrez Juan Cristóbal Sánchez Aranzazu González-del-Alba Roberto Hernández Miriam Méndez Blanca Cantos Beatriz Núñez Pedro A. C. Sousa Mariano Provencio Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors Frontiers in Cardiovascular Medicine cardiovascular event immune checkpoint inhibitors myocarditis cardiotoxicity risk factors |
| title | Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| title_full | Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| title_fullStr | Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| title_full_unstemmed | Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| title_short | Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| title_sort | assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors |
| topic | cardiovascular event immune checkpoint inhibitors myocarditis cardiotoxicity risk factors |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1062858/full |
| work_keys_str_mv | AT mariatorrente assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT mariatorrente assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT mariolablanco assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT fabiofranco assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT yagogaritaonaindia assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT virginiacalvo assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT anacollazolorduy assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT lourdesgutierrez assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT juancristobalsanchez assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT aranzazugonzalezdelalba assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT robertohernandez assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT miriammendez assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT blancacantos assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT beatriznunez assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT pedroacsousa assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors AT marianoprovencio assessingtheriskofcardiovasculareventsinpatientsreceivingimmunecheckpointinhibitors |